Immunogenetics of drug-induced skin blistering disorders. Part I: Perspective

Pharmacogenomics

Volumn 10, Issue 4, 2009, Pages 601-621

  Bowman, Clive ^a   Delrieu, Olivier ^b  

^a UNIVERSITY OF READING   (United Kingdom)

^b PGXIS   (United Kingdom)

Author keywords

Erythema multiforme; Human leukocyte antigen; Hypersensitivity; Lyell syndrome; Maculopapular erythema; MHC; Pharmacogenetics; Rash; Steven Johnsons syndrome; Toxic epidermal necrolysis

Indexed keywords

ABACAVIR; ALLOPURINOL; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME; GLUTATHIONE TRANSFERASE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; LAMOTRIGINE; OXICAM DERIVATIVE; PHENYTOIN; SULFAMETHOXAZOLE;

BEHCET DISEASE; BLISTER; BULLOUS SKIN DISEASE; CROSS REACTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG METABOLISM; ECOLOGICAL GENETICS; ETHNIC DIFFERENCE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HAPTEN CARRIER COMPLEX; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNE STABILITY; IMMUNOGENETICS; IMMUNOLOGICAL PARAMETERS; IMMUNOPATHOGENESIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR MIMICRY; PEMPHIGUS VULGARIS; PHARMACOGENETICS; PHENOTYPE; RASH; REVIEW; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VIRUS ACTIVATION; VIRUS REACTIVATION; VIRUS REPLICATION;

BLISTER; DRUG HYPERSENSITIVITY; EPIDERMAL NECROLYSIS, TOXIC; HLA ANTIGENS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; STEVENS-JOHNSON SYNDROME;

EID: 66949117847     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.11     Document Type: Review

References (157)

1. de Weck AL: Drug allergy, immunotherapy, immune complexes and anaphylaxis. Curr. Opin. Immunol. 2, 548-557 (1990).
2. Ingelman-Sundberg M: Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N. Engl. J. Med. 358 (6), 637-639 (2008).
3. Hirschhorn JN, Daly MJ: Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet. 6, 95-108 (2005).
4. Roses AD: Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. 5(9), 643-655 (2004).
5. Tsuchiya N, Ohashi J, Tokunaga K: Variations in immune response genes and their associations with multifactorial immune disorders. Immunol. Rev. 190, 169-181 (2002).
6. Lee A, Thomson J: Drug-induced skin reactions. In: Adverse Drug Reactions (2nd edition). Pharmaceutical Press, London, UK 125-156 (2006).
7. Lipsker D, Saurat J-H: Neutrophilic cutaneous lupus erythematosus at the edge between innate and acquired immunity? Dermatology 216, 283-286 (2008).
8. Williams DM: Non-infectious diseases of the oral soft tissue: a new approach. Adv. Dent. Res. 7(2), 213-219 (1993).
9. Alfirevic A, Naisbitt D: The 2nd international drug hypersensitivity meeting. Expert Opin. Drug Saf. 5(5), 729-734 (2006).
10. Lawlor DA: Evolution of class-I MHC genes and proteins: from natural selection to thymic selection. Ann. Rev. Immunol. 8, 23-63 (1990).
11. Pirmohamed M, Arbuckle J, Bowman C et al.: Investigation into the multi-dimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 8(12), 1661-1691 (2007).
12. Alves C, Souza T, Meyer I, Toralles P, Brites C: Immunogenetics and infectious diseases: special reference to the mayor histocompatibility complex. Braz. J Infect. Dis. 10(2), 122-131 (2006).
13. Cooke GS, Hill AVS: Genetics of susceptibility to human infectious disease Nat. Rev. Genetics 2, 967-977 (2001).
14. Hill AVS: The immunogenetics of human infectious diseases. Annu. Rev. Immunol. 16, 593-617 (1998).
15. Traherne JA: Human MHC architecture and evolution: implications for disease association studies. Int. J. Immunogenetics 35, 179-192 (2008).
16. Nepom GT. MHC genes in HLA-associated disease. Curr. Opin. Immunol. 2, 588-592 (1990).
17. Lyell A, Gordon AM, Dick HM, Sommerville RG: Mycoplasmas and erythema multiforme. Lancet 1116-1118 (1967).
18. Bowman C, Delrieu O: Immunogenetics of drug-induced 'blistering' disorders. Part II - Synthesis. Pharmacogenomics DOI: 10.2217/ PGS.09.23 (2009) (In press).
19. Gazit E, Loewenthal R: The immunogenetics of pemphigus vulgaris. Autoimmun. Rev. 4(1), 16-20 (2005).
20. Al-Otaibi LM, Porter SR, Poate TWJ: Behçet's disease: a review. J Dent. Res. 84(3), 209-222 (2005).
21. Sakane T, Suzuki N, Nagafuchi H: Etiopathology of Behçet's disease: immunological aspects. Yonsei Med. J. 38, 350-358 (1997).
22. Verity DH, Wallace GR, Vaughan RW, Stanford MR: Behçet's disease: from Hippocrates to the third millennium. Br. J. Ophthalmol. 87, 1175-1183 (2003).
23. Gatanga H, Yazaki H, Tanuma J et al.: HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 21, 264-265 (2007).
24. Gatanga H, Honda H, Oka S: Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics 9(2), 207-214 (2008).
25. Littera R, Carcassi C, Masal A et al.: HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 20, 1621-1626 (2006).
26. + T cells provides the immunogenetic basis for systemic drug hypersensitivity. Immunity 28, 822-832 (2008).
27. Mallal S, Nolan D, Witt C et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
28. Kindmark A, Jawaid A, Harbron CG et al.: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8(3), 186-195 (2007).
29. Greenspan NS: Conceptualizing immune responsiveness. Nat. Immunol. 8(1), 5-7 (2007).
30. Spritz RA: The genetics of generalized vitiligo and associated autoimmune diseases Pigment Cell. Res. 20, 271-278 (2007).
31. Feola DJ, Garvy BA: Combination exposure to zidovudine plus sulfamethoxazole-trimethoprim diminishes B-lymphocyte immune responses to pneumocystis murina infection in healthy mice. Clin. Vacc. Immunol. 13(2), 193-201 (2006).
32. Gogtay NJ, Bavdekar SB, Kshirsagai NA: Anticonvulsant hypersensitivity syndrome: a review. Expert Opin. Drug Saf. 4(3), 571-581 (2005).
33. Arroyo S, de la Morena A: Life-threatening adverse events of antiepileptic drugs Epilepsy Res. 47, 155-174 (2001).
34. Knowles SR, Shapiro LE, Shear NH: Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Safety 21(6), 489-501 (1999).
35. Hirsch Q, Weintraub DB, Buchsbaum R et al.: Predictors of lamotrigine-associated rash. Epilepsia 47(2), 318-322 (2006).
36. Arif H, Buchsbaum R, Weintraub D et al.: Comparison and Predictors of rash associated with 15 antiepileptic drugs. Neurology 68, 1701-1709 (2007).
37. Alvestad S, Brodtkorb E: Cross sensitivity of skin rash with current antiepileptic drugs. Epilepsia 46(Suppl. 6), 280 (2005).
38. Pichler WJ (Ed.): Drug hypersensitivity. Karger Publishers, Basel, Switzerland (2007).
39. Sanderson JP, Naisbitt DJ, Park BK: Role of bioactivation in drug-induced hypersensitivity reactions. AAPS J. 8(1), Article 7, E55-E64 (2006).
40. Demoly P, Viola M, Gomes ER, Romano A: Epidemiology and causes of drug hypersensitivity. In: Drug Hypersensitivity. Pichler WJ (Ed.). Karger, Switzerland 2-17 (2007).
41. Bustamante J, Boisson-Dupuis S, Jouanguy E et al.: Novel primary immunodeficiencies revealed by the investigation of paediatric infectious diseases. Curr. Opin. Immunol. 20, 39-48 (2008).
42. Pichler WJ: Immune mechanism of drug hypersensitivity. Immunol. Allergy Clin. N. Am. 24, 373-397 (2004).
43. Naisbitt DJ: Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnostic and predictive tests. Toxicology 194(3), 179-196 (2004).
44. Rottman JB: Key role of chemokines and chemokine receptors in inflammation, immunity, neoplasia, and infectious disease. Vet. Pathol. 36, 357-367 (1999).
45. Mandal BK: Herpes zoster in the immunocomprized populations. Indian J. Dermatol. 51(4), 235-243 (2006).
46. Gaig P, Garcia-Ortega P, Baltasar M, Bartra J: Drug neosensitization during anticonvulsant hypersensitivity syndrome. J. Investig. Allergol. Clin. Immunol. 16(5), 321-326 (2006).
47. Barton ES, White OW, Cathelyn JS et al.: Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 447, 326-330 (2007).
48. Steinman L: Escape from 'Horror Autotoxicus': pathogenesis and treatment of autoimmune disease. Cell 80, 7-10 (1995).
49. Strogatz SH: Nonlinear dynamics and chaos: with applications to physics, biology, chemistry and engineering. Perseus Books Group, TN, USA (2001).
50. Newport MJ, Goetghebuer T, Marchant A: Hunting for immune response regualtory genes: vaccination studies in infant twins. Expert Rev. Vaccines 4(5), 739-746 (2005).
51. Sojka DK, Huang Y-H, Fowell DJ: Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target. Immunology 124, 13-22 (2008).
52. Waldmann H: Special regulatory T cell review: the suppression problem! Immunology 123, 11-12 (2008).
53. Price P, Keane NM, Stone SF, Cheong KY, French MA: MHC haplotypes affect the expression of opportunistic infections in HIV patients. Hum. Immunol. 62, 157-164 (2001).
54. Lawn SD: Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy. Curr. Opin. Infect. Dis. 20, 482-488 (2007).
55. Shelburne SA, Hamill RJ, Rodriguez-Barradas MC et al.: Immune reconstitution inflammatory syndrome. emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 81(3), 213-227 (2002).
56. Shelburne SA, Hamill RJ: The immune reconstitution inflammatory syndrome. AIDS Rev. 5, 67-79 (2003).
57. French MA, Lenzo N, John M et al.: Immune restoration disease after treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Medicine 1, 107-115 (2000).
58. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome(DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol. Int. 55, 1-8 (2006).
59. Knysz B, Bolanowski M, Klimczak M, Gladysz A, Zwolinska K: Graves' disease as an immune reconstitution syndrome in a HIV-1-positive patient commencing effective antiretroviral therapy: case report and literature review. Viral Immunology 19(1), 102-107 (2006).
60. Karavellas M P, Plummer DJ, Macdonald JC et al.: Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J. Infect. Dis. 179, 697-700 (1999).
61. Rauz S, Murray PI: Changing patterns of HIV related ocular disease. Sex Transm. Infect. 75, 18-20 (1999).
62. Race EM, Reimann KA, Adelson-Mitty J et al.: Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV disease. Lancet 351, 252-255 (1998).
63. Fishman JE, Hollender ES, Saraf-Lavi E, Ramsinghani R, Narita M, Ashkin D: Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy. Am. J. Roenterol. 174, 43-49 (2000).
64. John M, Flexman J, French M: Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 12, 2289-2293 (1998).
65. Canzano JC, Reed JB, Morse LS: Vitreomacular traction syndrome following highly active antiretroviral therapy in AIDS patients with cytomegalovirus retinitis. Retina 18, 443-447 (1998).
66. Goulder PJR, Klenerman P: Cytotoxic T lymphocytes and viral adaptation in HIV infection. Curr. Opin. HIV AIDS 1, 241-248 (2006).
67. Schrier RD, Freeman WR, Wiley CA, McCutchan JA; HNRC Group: Immune predispositions for cytomegalovirus retinitis in AIDS. J. Clin. Invest. 95, 1741-1746 (1995).
68. Brice SL, Krzemien D, Weston WL, Huff JC: Detection of herpes simplex virus DNA in cutaneous lesions of erythema multiforme. J. Invest. Dermatol. 93, 183-187 (1989).
69. Miura S, Smith CC, Burnett JW, Aurelian L: Detection of viral DNA within skin of healed recurrent herpes simplex infection and erythema multiforme lesions. J. Invest. Dermatol. 98, 68-72 (1992).
70. Ahmed AR, Mohimen A, Yunis EJ et al.: Linkage of pemphigus vulgaris antibody to the major histocompatibility complex in healthy relatives of patients. J Exp. Med. 177, 419-424 (1993).
71. Chan PT: Review on pathogenesis of pemphigus. Hong Kong Dermatology Venereology Bulletin 10(2), 62-68 (2002).
72. Alon U: An Introduction to Systems Biology. Design Principles of Biological Circuits. Chapman & Hall/CRC, USA (2007).
73. Bonabeau E, Dorigo M, Theraulaz G: Swarm Intelligence: From Natural to Artificial Systems. Oxford University Press, UK (1991).
74. Ueta M, Sotozono C, Inatomi T, Tashiro K, Hamuro J, Kinoshita S: Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome. Br. J. Ophthalmol. 91, 962-965 (2007).
75. Baum H: Mitochondrial antigens, molecular mimicry and autoimmune disease. Biochim. Biophys. Acta 1271(1), 111-121 (1995).
76. Baum H, Brusic V, Choudhuri K, Cunningham P, Vergani D, Peakman M: MHC molecular mimicry in diabetes. Nat. Med. 1(5), 388 (1995).
77. Baum H, Butler P, Davies H, Sternberg M, Burroughs A: Autoimmune disease and molecular mimicry: an hypothesis. Trends biochem. Sci. 18, 140-144 (1993).
78. Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y: HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J. Exp. Med. 181(5), 1835-1845 (1995).
79. Oldstone MBA: Molecular mimicry and autoimmune disease. Cell 50, 819-820 (1997).
80. Roy CR, Mocarski ES: Pathogen subversion of cell-intrinsic innate immunity. Nat. Immunol. 8(11), 1179-1187 (2007).
81. Krauss G: Current understanding of delayed anticonvulsant hypersensitivity reactions. Epilepsy Curr. 6(2), 33-37 (2006).
82. Pichler WJ: Delayed drug hypersensitivity reactions. Ann. Intern. Med. 139, 683-693 (2003).
83. Presland RB, Jurevic RJ: Making sense of the epithelial barrier: what molecular biology and genetics tell us about the functions of oral mucosal and epidermal tissues. J. Dental Education 66(4), 564-574 (2002).
84. Prugnolle F, Manica A, Charpentier M, Gugan JF, Guernier V, Balloux F: Pathogen-driven selection and worldwide HLA class I diversity. Curr. Biol. 15, 1022-1027 (2005).
85. Carrington M, O'Brien SJ: The influence of HLA genotype on AIDS. Annu. Rev. Med. 54, 535-551 (2003).
86. Gregersen PK, Silver J, Winchester RJ: The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30(11), 1205-1213 (1987).
87. Yang Q, Khoury MJ, Sun F, Flanders WD: Case-only design to measure gene-gene interaction. Epidemiology 10, 167-170 (1999).
88. Zinkernagel R: On observing and analyzing disease versus signals. Nat. Immunol. 8(1), 8-10 (2007).
89. Hunter DJ: Gene-environment interactions in human diseases. Nat. Rev. Genet. 6, 287-298 (2005).
90. Batstone L, Reilly M, Rader DJ, Foulkes AS: MDR and PRP: a comparison of methods for high-order genotype-phenotype associations. Hum. Hered. 58(2), 82-92 (2004).
91. Jannot AS, Essioux L, Reese MG, Clerget-Darpoux F: Improved use of SNP information to detect the role of genes. Genet. Epidemiol. 25(2), 158-167 (2003).
92. Nelson MR, Kardia SL, Ferrell RE, Sing CF: A combinatorial partitioning method to identify multilocus genotypic partitions that predict quantitative trait variation. Genome Res. 11(3), 458-470 (2001).
93. Ritchie MD, Hahn LW, Roodi N et al.: Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am. J. Hum. Genet. 69(1), 138-147 (2001).
94. Warren LL, Hughes AR, Lai EH et al.: Use of pair-wise market combinations and recursive partitioning in a pharmacogenetic genome-wide scan. Pharmacogenomics J. 1-10 (2006).
95. Garcia-Closas M, Malats N, Silverman D et al.: NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366, 649-659 (2005).
96. Greenland S: Tests for interaction in epidemiologic studies: a review and a study of power. Stat. Med. 2, 243-251 (1983).
97. Harley JB, Kelly JA, Kaufman KM: Unraveling the genetics of systemic lupus erythematosus. Springer Semin. Immun. 28, 119-130 (2006).
98. Sestak AL, Nath SK, Sawalha AH, Harley JB: Current status of lupus genetics. Arthritis Res. Ther. 9(3), 210 (2007).
99. Wakeland EK, Liu K, Graham RR, Behrens TW: Delineating the genetic basis of systemic lupus erythematosus. Immunity 15, 397-408 (2001).
100. Kyttaris VC, Krishnan S, Tsokos GC: Systems biology in systemic lupus erythematosus: integrating genes, biology and immune function. Autoimmunity 39 (8), 705-709 (2006).
101. Davies TF: Really significant genes for autoimmune thyroid disease do not exist - so how can we predict disease. Thyroid 17(11), 1027-1029 (2007).
102. Hanage WP, Fraser C, Spratt BG: Fuzzy species among recombinogenic bacteria. BMC Biol. 3, 6-17 (2005).
103. Schaefer JA, Wilson CC: The fuzzy structure of populations. Can. J. Zool. 80, 2235-2241 (2002).
104. van Regenmortel MHV. From absolute to exquisite specificity. Reflections on the fuzzy nature of species, specificty and antigenic sites. J. Immune Meth. 216, 37-48 (1998).
105. Wittgenstein L: Philosophical Investigations. Macmillan, NY, USA (1953).
106. Phillips EJ, Wong GA, Kaul R et al.: Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 19, 979-987 (2005).
107. Mallal S, Phillips E, Carosi G et al.: The PREDICT-1 study: a randomized, double-blind trial to determine the clinical utility of HLA-B*5701 pharmacogenetic screening for abacavir hypersensitivity in HIV-infected patients (Study CNA106030). N. Engl. J. Med. 358, 568-579 (2008).
108. Saag M, Balu R, Phillips E et al.: High sensitivity of HLA-B*5701 in immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 46, 1111-1118 (2008).
109. Ioannidis JPA: Non-replication and inconsistency in the genome-wide association setting. Hum. Hered. 64, 203-213 (2007).
110. Matzinger P: Friendly and dangerous signals: is the tissue in control. Nat. Immunol. 8(1), 11-13 (2007).
111. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK: The danger hypothesis-potential role in idiosyncratic drug reactions. Toxicology 181-182, 55-63 (2002).
112. Pichler WJ: Direct T-cell stimulations by drugs-bypassing the innate immune system. Toxicology 209, 95-100 (2005).
113. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ: Direct, MHC-dependent presentation of the drug sulfamethoxazole to human αβ T cell clones. J. Clin. Invest. 100(1), 136-141 (1997).
114. Talal N: Autoimmunity and the immunologic network. Arthritis Rheum. 21(7), 853-861 (1978).
115. Ueta M, Sotozono C, Tokunaga K, Yabe T, Kinoshita S: Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese. Am. J. Opthalmol. 143(2), 367-368 (2007).
116. Ueta M, Sotozono C, Inatomi T, Kojima K, Hamuro J, Kinoshita S: Association of IL4R polymorphisms with Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 120(6), 1457-1459 (2007).
117. Fan C, Oh DS, Wessels L et al.: Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355, 560-569 (2006).
118. Scott I, O'Shea J, Bunce M et al.: Molecular typing shows a high level of HLA class I incompatibility in serologically well matched donor/ patient pairs: implications for unrelated bone marrow donor selection. Blood92(12), 4864-4871 (1998).
119. Chung W, Hung S, Hong H et al.: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428(6982), 486 (2004).
120. Hung S, Chung W, Jee S et al.: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16(4), 297-306 (2006).
121. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernandez-Viga MA: Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum. Immunol. 62, 1009-1030 (2001).
122. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M: HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7, 813-818 (2006).
123. Lonjou C, Thomas L, Borot N et al.: A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmaogenomics J. 6(4), 265-268 (2006).
124. Hung S, Chung W, Liou L et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102(11), 4134-4139 (2005).
125. Hetherington S, Hughes A, Mosteller M et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359(9312), 1121-1122 (2002).
126. Jankowski J, Crombie I, Jankowski R: Behçet's syndrome in Scotland. Postgrad. Med. J. 68, 566-570 (1992).
127. Nishimura Y, Oiso M, Fujisao S et al.: Peptide-based molecular analyses of HLA class II-associated susceptibility to autoimmune diseases. Int. Rev. Immunol. 17(5-6), 229-262 (1998).
128. Tishkoff SA, Kidd KK: implications of biogeography of human populations for 'race' and medicine. Nat. Gene. Suppl. 36(11), S21-S27 (2004).
129. Voorter CEM, Mulkers E, Liebelt P, Sleyster E, van den Berg-Loonen EM: Reanalysis of sequence-based HLA-A, -B and -Cw typings: how ambiguous is today's SBT typing tomorrow. Tissue Antigens 70, 383-389 (2007).
130. Muller-Hilke B, Michison NA: The role of HLA promoters in autoimmunity. Curr. Pharm. Des. 12, 3743-3752 (2006).
131. Hughes AR, Mosteller M, Barisal AT et al.: Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5(2), 203-211 (2004).
132. Yunis EJ, Larsen CE, Fernandez-Vina M et al.: Inheritable variable sizes of DNA stretches in the human MHC: conserved extended haplotypes and their fragments or blocks. Tissue Antigens 62, 1-20 (2003).
133. Feng ML, Guo XJ, Zhang JY et al.: Study on the haplotypes of MICA and MICB microsatellite and HLA-B locus in the Guangzhou Han population. Tissue Antigens 64(3), 281-285 (2004).
134. Grubic Z, Stingl K, Zunec R, Car H, Cecuk-Jelicic E, Brkljacic-Kerhin V: Linkage disequilibria between human leucocyte antigen-B and closely linked microsatellites in the Croatian population. Tissue Antigens 69, 86-94 (2006).
135. Choukri F, Chakib A, Himmich H, Hue S, Caillat-Zucman S: HLA-B*51 and B*15 alleles confer predisposition to Behçet's disease in Moroccan patients Hum. Immunol. 62(2), 180-185 (2001).
136. Mizuki N, Ota M, Kimura M et al.: Triplet repeat polymorphism in the transmembrane region of the MICA gene: A strong association of six GCT repetitions with Behçet disease. Proc. Natl Acad. Sci. USA 94, 1298-1303 (1997).
137. Park S-H, Park K-S, Seo Y-I et al.: Association of MICA polymorphism with HLA-B51 and disease severity in Korean patients with Behçet's disease. J. Korean Med. Sci. 17, 366-370 (2002).
138. Mizuki N, Ota M, Yabuki K et al.: Localization of the pathogenic gene of Behçt's disease by microsatellite analysis of three different populations. Invest. Ophthalmol. Vis. Sci. 41, 3702-3708 (2000).
139. Ahmad T, Wallace GR, James T et al.: Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polyniorphisms. Arthritis Rheum. 48(3), 807-813 (2003).
140. Gul A, Uyar TA, Inanc M et al.: A weak association of HLA-B*2702 with Behçet's disease. Genes Immun. 3, 368-372 (2002).
141. Chao MJ, Barnardo MCNM, Lui G-Z et al.: Transmission of class I/II multi-locus haplotypes and multiple sclerosis susceptibility: accounting for linkage disequilibrium. Hum. Mol. Gene. 16(16), 1951-1958 (2007).
142. Trowsdale J: Genetic and functional relationships between MHC and NK receptor genes. Immunity 15, 363-374 (2001).
143. Vilches C, Parham P: KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu. Rev. Immunol. 20, 217-251 (2002).
144. Boyton RJ, Altmann DM: Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin. Exp. Immunol. 149, 1-8 (2007).
145. Khakoo SI, Carrington M: KIR and disease: a model system or a system of models. Immunol. Rev. 214, 186-201 (2006).
146. Parham P: MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immunol. 5, 201-214 (2005).
147. Sokal RR, Sneath PH A: Principles of Numerical Taxonomy. Freeman WH (Ed.). CA, USA (1963).
148. Newport MJ, Goetghebuer T, Weiss HA et al.: Genetic regulation of immune responses to vaccines in early life. Genes Immun. 5, 122-129 (2004).
149. Colwell RK: Niche: a bifurcation in the conceptual lineage of the term. In: Keywords in Evolutionary Biology. Keller EF, Lloyd EA (Eds). Harvard University press, MA, USA 241-248 (1992).
150. Dean M, Carrington M, O'Brien SJ: Balanced polymorphisms selected by genetic versus infectious human disease. Annu. Rev. Genomics Hum. Genet. 3, 263-292 (2002).
151. Westendorp RGJ, van Dunne FM, Kirkwood TBL, Helmerhorst FM, Huizinga TWJ: Optimizing human fertility and survival. Nat. Med. 7(8), 873 (2001).
152. Man CBL, Kwan P, Baum L et al.: Association between HLA-B. 1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48(5), 1015-1018 (2007).
153. Lonjou C, Borot N, Sekula P et al.: A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necfolysis related to five high-risk drugs. Pharmacogenetics Genomics 18, 99-107 (2008).
154. Mikiko T, Koji H: Drug-induced hypersensitivity syndrome (DIHS). Hypothesis of HHV-6 reactivation in DIHS. Vis. Dermatol. 4(10), 1046-1049 (2005).
155. Betterle C, Spadaccino AC, Presotto F et al.: The number of markers of pancreatic autoimmunity is proportional to the risk for Type 1 diabetes mellitus in Italian and English patients with organ-specific autoimmune diseases. Ann. NY Acad. Sci. 958, 276-280 (2002).
156. Pomerening JR, Sontag ED, Ferrell JE Jr: Builiding a cell cycle oscillator: hysteresis and bistability in the activation of Cdc2. Nat. Cell. Biol. 5, 346-351 (2003).
157. Tyson JJ, Chen KC, Novak B: Sniffers, buzzers, toggles and blinkers: dynamics of regulatory and signaling pathways in the cell. Curr. Opin. Cell. Biol. 15, 221-231 (2003).